Global prevalence of CFTR variants with respect to their responsiveness to elexacaftor-tezacaftor-ivacaftor
Journal of Cystic Fibrosis · 2025-11 · 24 (6) · 1017-1026
DOI: 10.1016/j.jcf.2025.10.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2025-11. Verfasst von P-R Burgel und 21 weiteren Autor:innen. Beteiligte Einrichtung: National Reference CF center and Respiratory Medicine, Cochin Hospital APHP and Université Paris Cité, Institut Cochin (InsermU1016), Paris, France. …. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Aminophenols, Quinolones. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Elexacaftor-tezacaftor-ivacaftor (ETI) is mostly approved in people with cystic fibrosis (pwCF) with a p.Phe508del CFTR variant. The US Food and Drug Administration (FDA) approved ETI for an additional 177 rare CFTR variants and studies identified 7 non-FDA approved variants also responsive to ETI. The global impact of expanding the ETI label to rare responsive CFTR variants on the number of eligible pwCF is unknown. METHODS: Data were obtained from CF registries and individual CF clinics in countries without registries. Individuals were classified according to five mutually-exclusive categories (1) at least one p.Phe508del variant (2) at least one of the 177 FDA-approved variants (3) at least one non-FDA-approved variant responsive to ETI (4) two variants resulting in no CFTR protein (5) all other variants. The first 3 groups were considered responsive to ETI, group 4 was nonresponsive and group 5 of undetermined responsiveness. RESULTS: Data were obtained from 95,838 pwCF living in 69 countries: 78,566 (82.0 %) had at least one p.Phe508del, 6175 (6.4 %) at least one FDA-approved variants, and 2981 (3.1 %) at least one non-FDA-approved responsive variants. Two variants resulting in no CFTR protein were found in 3574 (3.7 %) and other variant combinations in 4490 (4.7 %). The prevalence of p.Phe508del ranged from 7 % to 98 % in individual countries and expanding the eligibility to responsive non-p.Phe508del variants resulted in greatest eligibility increase in countries with low p.Phe508del prevalence. CONCLUSION: Expanding the label of ETI to rare responsive CFTR variants will make at least 91.5 % of pwCF eligible to this disease-modifying therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Reference CF center and Respiratory Medicine, Cochin Hospital APHP and Université Paris Cité, Institut Cochin (InsermU1016), Paris, France. Electronic address: pierre-regis.burgel@aphp.fr.
- Department of Clinical Sciences and Community Health, Laboratory of Medical Statistics, Biometry and Epidemiology "G. A. Maccacaro", Università degli Studi di Milano, Milan, Italy.
- Cystic Fibrosis Foundation, Bethesda, MD, USA.
- Department of Biology and Medical Genetics, Charles University 2nd Faculty of Medicine and Motol University Hospital, Prague, Czechia.
- Pediatric Pulmonary and Sleep Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
- Division of Pediatric Pulmonology, Marmara University Faculty of Medicine, Istanbul, Turkey.
Zitieren
APA
Burgel, P. R., Orenti, A., Cromwell, E., Macek, M., Gutierrez, H. H., Karadag, B., Faro, A., van Rens, J. G., Naehrlich, L., Bakkeheim, E., Carr, S. B., Lindblad, A., Zolin, A., Lammertyn, E., Ruseckaite, R., Zampoli, M., Byrnes, C. A., da Silva-Filho, L., Elbert, A., …, & on the behalf of the ECFSPR scientific committee and the Global CF Registry Collaboration (2025). Global prevalence of CFTR variants with respect to their responsiveness to elexacaftor-tezacaftor-ivacaftor. Journal of Cystic Fibrosis, 24(6), 1017-1026. https://doi.org/10.1016/j.jcf.2025.10.007
Vancouver
Burgel PR, Orenti A, Cromwell E, Macek M, Gutierrez HH, Karadag B, et al. Global prevalence of CFTR variants with respect to their responsiveness to elexacaftor-tezacaftor-ivacaftor. Journal of Cystic Fibrosis. 2025;24(6):1017-1026. doi:10.1016/j.jcf.2025.10.007
BibTeX
@article{Burgel2025,
author = {Burgel, P-R and Orenti, A and Cromwell, E and Macek, M and Gutierrez, H H and Karadag, B and Faro, A and van Rens, J G and Naehrlich, L and Bakkeheim, E and Carr, S B and Lindblad, A and Zolin, A and Lammertyn, E and Ruseckaite, R and Zampoli, M and Byrnes, C A and da Silva-Filho, Lvrf and Elbert, A and Cheng, S Y and Stephenson, A L and on the behalf of the ECFSPR scientific committee and the Global CF Registry Collaboration, on the behalf of the ECFSPR scientific committee and the Global CF Registry Collaboration},
title = {Global prevalence of CFTR variants with respect to their responsiveness to elexacaftor-tezacaftor-ivacaftor},
journal = {Journal of Cystic Fibrosis},
year = {2025},
volume = {24},
number = {6},
pages = {1017--1026},
doi = {10.1016/j.jcf.2025.10.007}
}
EUVIMED